The MTA will replace Sagg Road bridge in Sagaponack, Cranberry Hole Road bridge in Amagansett and River Avenue bridge in ...
Structural audits of flyovers should be conducted every five years; PWD will take up Shadipur and Zakhira, among the city’s ...
Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial. Emotional ...
When the kidney cancer known as renal cell carcinoma spreads to other places (metastatic) or comes back after remission (recurrent), you may need different types of treatment. Surgery can remove renal ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
The combination of belzutifan (Welireg) and lenvatinib (Lenvima) led to superior outcomes, compared with cabozantinib (Cabometyx), in a phase 3 trial of patients with advanced clear cell renal cell ...
The last time I wrote about Allogene Therapeutics, Inc. (ALLO) it was in a Seeking Alpha article entitled "Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products." I noted the ...
Both trials are ongoing and will report on overall survival at a subsequent analysis. Findings showed the trial met its primary endpoint demonstrating a statistically significant and clinically ...
As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...
Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...
Belzutifan improved quality-adjusted survival time over everolimus in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. Despite longer grade 3/4 toxicity duration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results